摘要
自从第一个促红细胞生成素(erythropoietin,EPO)药物于1988年上市,迄今已超过30年时间,本类药物在贫血治疗中的有效性和安全性已经过广泛验证,2017年度国际总销售额超过55亿美元。本文就当前国际和国内主要EPO类已上市药物的特点、适应证及使用方式、有效性及安全性、市场情况及趋势等进行了总结和简要分析,显示EPO类药物治疗贫血安全有效,长效EPO品种已逐步取代短效EPO品种成为国际市场主流,而国内虽然尚无长效EPO品种上市,但在未来3~5年将陆续有国产长效EPO品种投放市场。
Since the approval of Epogen in 1988,erythropoietin(EPO)-based recombinant protein agents have been used for the therapy of anemia for over thirty years.In this context,we briefly introduce and summarize the characteristics,indications,efficacy and safety profiles of EPO-based recombinant protein agents currently available on the market,and make a brief analysis to estimate the market trend in the near future.In summary,EPO-based recombinant protein agents have the ability to correct anemia with controlled safety concerns.At the same time,instead of EPOs with short-term effects,EPOs with longer half-lives have occupied the majority of international market shares.
作者
高峰
任利文
李晓雯
杨春
王金华
杜冠华
GAO Feng;REN Li-wen;LI Xiao-wen;YANG Chun;WANG Jin-hua;DU Guan-hua(Buchang(Beijing)Pharmaceutical R&D Co.,Lud.,Bejing 102600,China;Institute of Materia Medica,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100050,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2020年第10期1110-1117,共8页
Chinese Journal of New Drugs
基金
国家“重大新药创制”科技重大专项资助项目(2018ZX09711001-005-025,2018ZX09733001-001-003)
国家自然科学基金资助项目(81573454)
中国医学科学院协同创新工程(2016-I2M-3-007)
北京市自然科学基金资助项目(7172142)